Therapeutic anticoagulation is indicated for a variety of circumstances and conditions in
several fields of medicine to prevent or treat venous and arterial thromboembolism …

Anticoagulants are the cornerstone for prevention and treatment of thrombosis but are not
completely effective, and concerns about the risk of bleeding continue to limit their uptake …

As the third most common vascular disease, venous thromboembolism is associated with
significant mortality and morbidity. Pathogenesis underlying venous thrombosis is still not …

During the past decade, emergence of direct oral anticoagulants (DOACs) has drastically
improved the prevention of thrombosis. However, several unmet needs prevail in the field of …

Thrombotic complications in patients with end-stage kidney disease are frequent. While
being a lifesaving treatment for these patients, hemodialysis introduces a …

Direct oral anticoagulants (DOACs) that inhibit the coagulation proteases thrombin or factor
Xa (FXa) have replaced warfarin and other vitamin K antagonists (VKAs) for most indications …

Thrombosis remains one of the leading causes of death in the world. The history of
anticoagulation has evolved considerably from non-specific drugs (ie, heparins and vitamin …

Despite major advancements in the development of safer and more effective anticoagulant
agents, bleeding complications remain a significant concern in the treatment of …

Factor XIa (FXIa) in the intrinsic pathway of the coagulation process has been proven to be
an effective and safe target for anticoagulant discovery with limited or no bleeding …

Hematopoietic stem cell transplantation (HCT) represents a curative treatment option for
certain malignant and nonmalignant hematological diseases. Conditioning regimens before …